GLSI — Recent News Coverage

All news mentioning GLSI in ESEN's AI-graded feed

News stories with GLSI as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on GLSI. See /coverage/GLSI for the 30-day aggregate.

7 articles Updated: 2026-11-18 06:45 UTC Filter: Ticker: $GLSI
RTTNEWS.COM · 2026-11-17 NEUTRAL BULLISH CORR0.55

Greenwich LifeSciences Stock Up 23% On Immunotherapy Trial Update

$GLSI
◈ ESEN AI
GLSI gained 23% following the acceptance of two abstracts from its Phase III FLAMINGO-01 trial for publication at the 2026 San Antonio Breast Cancer Symposium. This represents meaningful clinical validation for the comp…
MANILATIMES.NET · 2026-11-17 LOW NEUTRAL CORR0.15

Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026

$GLSI
◈ ESEN AI
GLSI announced acceptance of two abstracts for presentation at the San Antonio Breast Cancer Symposium (SABCS) 2026, a scheduled conference disclosure. This is a procedural milestone in the clinical trial communication …
RTTNEWS.COM · 2026-08-10 LOW NEUTRAL CORR0.15

Greenwich LifeSciences Stock Gains 4% After Extending Share Lock-Up

$GLSI
◈ ESEN AI
GLSI shares rallied 4.5% following a board announcement to extend the lock-up period for insiders and pre-IPO investors through January 31, 2027. This procedural disclosure is a routine governance action that signals ma…
MANILATIMES.NET · 2026-07-22 NEUTRAL BULLISH CORR0.42

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

$GLSI
◈ ESEN AI
Greenwich LifeSciences (GLSI) has secured regulatory clearance to expand its Phase III FLAMINGO-01 trial into the United Kingdom, broadening the geographic footprint for its breast cancer recurrence immunotherapy candid…
MANILATIMES.NET · 2026-07-20 NEUTRAL NEUTRAL CORR0.15

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

$GLSI
◈ ESEN AI
GLSI announced routine clinical updates on FLAMINGO-01, its Phase III trial evaluating GLSI-100, an immunotherapy candidate for breast cancer recurrence prevention. The company is a clinical-stage biotech with limited c…
SEEKINGALPHA.COM · 2026-07-16 LOW BULLISH CORR0.35

Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI)

$GLSI
◈ ESEN AI
GLSI represents a concentrated single-asset biotech thesis centered on GLSI-100, a clinical-stage immunotherapy targeting HER2-positive breast cancer. The article frames this as an overlooked opportunity, suggesting mar…
MARKETS.BUSINESSINSIDER.COM · 2026-07-09 HIGH BULLISH CORR0.72

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

$GLSI
◈ ESEN AI
Greenwich LifeSciences (GLSI) achieved a significant regulatory milestone with European approval for commercially manufactured GP2 in the FLAMINGO-01 trial. This represents a transition from clinical-stage manufacturing…
EXPLORE OTHER FILTERS